Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Operating Margin (2021 - 2025)

Historic Operating Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 102.64%.

  • Rhythm Pharmaceuticals' Operating Margin rose 293400.0% to 102.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 106.81%, marking a year-over-year increase of 1291400.0%. This contributed to the annual value of 204.04% for FY2024, which is 340700.0% up from last year.
  • Rhythm Pharmaceuticals' Operating Margin amounted to 102.64% in Q3 2025, which was up 293400.0% from 93.39% recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Operating Margin peaked at 93.39% during Q2 2025, and registered a low of 98280.0% during Q1 2021.
  • Its 5-year average for Operating Margin is 6730.04%, with a median of 458.03% in 2023.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Operating Margin soared by 947625800bps in 2022 and then crashed by -806800bps in 2024.
  • Rhythm Pharmaceuticals' Operating Margin (Quarter) stood at 2806.22% in 2021, then skyrocketed by 83bps to 478.99% in 2022, then skyrocketed by 64bps to 170.28% in 2023, then skyrocketed by 42bps to 98.63% in 2024, then dropped by -4bps to 102.64% in 2025.
  • Its Operating Margin was 102.64% in Q3 2025, compared to 93.39% in Q2 2025 and 143.73% in Q1 2025.